Innovation
1 December 202413.3 min readBased originally upon the research of the human microbiome carried out at the Wellcome Sanger Institute, Microbiotica was spun out as a microbiome therapeutics company in 2016. Today, Microbiotica is advancing steadily towards introducing transformational microbiome-based therapeutics and biomarkers in areas of high medical need, with first clinical trials – underpinned by a landmark £50m investment during 2022 – starting soon.
6 February 20249 min readThree vaccine targets discovered by the Wellcome Sanger Institute focus on targeting animal trypanosomiasis in an effort to find a cure for a disease that causes billions in economic losses in one of the poorest regions on earth. These losses fall heavily on small holders, who are often heavily dependent on livestock for their livelihood.
16 January 20248.2 min readBased on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
14 January 20249.3 min readDespite much progress that has been made to battle the disease, it remains a significant global healthcare challenge. By the 1970s, through public health measures such as the use of insecticides and anti-malarial drugs, the disease was virtually eliminated from the more affluent regions of the globe, but sadly it remains endemic in most of the tropical and subtropical regions of the world today, disproportionately affecting poor and vulnerable populations. It is found in more than 100 countries mainly in tropical regions of the world, including: large areas of Africa and Asia, Central and South America, Haiti and the Dominican Republic, parts of the Middle East and some Pacific islands. In regions where transmission remains high, it is often the leading cause of illness and death.
12 January 20246.5 min readKymab was a therapeutic antibody company based in Cambridge, UK, developing novel solutions in drug and vaccine development. Using its unique technology with roots in the laboratories of the Wellcome Sanger Institute, the company developed broad diversity, high-quality human antibodies. Kymab's therapeutics were designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases.
10 January 20248.2 min readCOSMIC is an online catalogue of somatic mutations in cancer, a gold standard data resource of global impact in the field of cancer genomics. The database has utility for basic research into the mechanisms of cancer but is also relevant for pharmaceutical R&D activities in oncology as well as the development of products and services in cancer diagnosis and patient stratification.
21 November 20239 min readWe spoke to Dr Iñigo Martincorena, group leader at the Wellcome Sanger Institute and academic co-founder of Quotient Therapeutics. Quotient is a new company leveraging Sanger Institute research to innovate the way drugs are discovered.
